AstraZeneca PLC (AZN) News
Follow AstraZeneca PLC (AZN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 250 public stories across 58 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
AstraZeneca Reports Q3 Revenue of $16.21 Billion; Oncology Rises 17%
The headline also reports a decline for Farxiga and an Etcamah miss; it does not specify what Etcamah missed.
EQUITY | Oct 31, 2026, 08:04 AM UTC
M
AstraZeneca Shares Rise 7.65% to $187.75
AstraZeneca shares climbed 7.65% to $187.75 at 12:40 p.m. ET on October 30. Reuters reported a restructuring overhaul alongside quarterly results, with a $2 billion cost ceiling.
EQUITY | Oct 30, 2026, 06:46 PM UTC
M
AstraZeneca Launches $1.5 Billion Cost-Savings Program
AstraZeneca said it is launching the program to free up resources for investment in its drug pipeline.
EQUITY | Oct 30, 2026, 02:58 PM UTC
M
AstraZeneca CEO Sees Over $20 Billion in Potential Sales From 2027 Trial Readouts
CEO Pascal Soriot said 2027 drug trial readouts could generate over $20 billion in peak annual sales. The company also unveiled a restructuring program targeting $1.5 billion in annual savings by 2029.
EQUITY | Oct 30, 2026, 11:38 AM UTC
M
European session market picture: S&P 500 -1.04%, Nasdaq 100 -2.48%; EUR/USD +0.15%, WTI +1.99%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 1.04 percent, Nasdaq futures is down 2.48 percent, Dow futures is up 0.15 percent and Russell futures is down 0.45 percent. In currencies, the do
EQUITY | Oct 30, 2026, 11:30 AM UTC
M
AstraZeneca Reports Third-Quarter Revenue of $16.21B
EQUITY | Oct 30, 2026, 11:05 AM UTC
M
AstraZeneca Reports Q3 and Nine-Month 2026 Results
AstraZeneca cited continued strong commercial performance and 12 positive Phase III programme readouts in the year to date.
EQUITY | Oct 30, 2026, 11:00 AM UTC
M
AstraZeneca Q3 Adjusted Earnings and Revenue Rise, Outlook Reaffirmed
EQUITY | Oct 30, 2026, 10:07 AM UTC
M
AstraZeneca Reports 7% Nine-Month Revenue Growth, Reiterates FY26 Guidance
Revenue for the nine months ended September 30 rose 7% to $46.88 billion. Reported EPS increased 10% to $5.62, while operating profit rose 10% to $11.80 billion and underlying earnings grew 11% to $16.70 billion.
EARNINGS | Oct 30, 2026, 09:58 AM UTC
H
AstraZeneca 3Q Results Beat Expectations, JPMorgan Says
J.P. Morgan analysts said AstraZeneca beat expectations on revenue and the bottom line and reiterated its 2026 and 2030 guidance. The analysts expect a positive share reaction.
EARNINGS | Oct 30, 2026, 07:46 AM UTC
M
AstraZeneca Reports Third-Quarter Revenue and Profit Growth
AstraZeneca said third-quarter revenue and profit increased, with strong cancer-drug sales offsetting the effect of patent expirations.
EQUITY | Oct 30, 2026, 07:40 AM UTC
M
AstraZeneca launches savings programme targeting $1.5 billion in benefits
AstraZeneca said the restructuring programme will support pipeline investment and help keep it on track to generate $80 billion in annual revenue by 2030. It was announced alongside third-quarter results.
EQUITY | Oct 30, 2026, 07:08 AM UTC
M
AstraZeneca 3Q Farxiga Sales Fall 25% at Constant Currency
Farxiga sales were $1.605 billion in the third quarter, down 25% at constant currency.
EARNINGS | Oct 30, 2026, 07:06 AM UTC
M
AstraZeneca Expected to Report Earnings of $2.60 per Share
An earnings preview expects AstraZeneca to post earnings of $2.60 per share.
EQUITY | Oct 28, 2026, 07:34 AM UTC
M
Enhertu Wins EU Approval for Early Breast Cancer Treatment
Enhertu has received EU approval to treat HER2-positive early breast cancer.
REGULATION | Oct 27, 2026, 12:45 PM UTC
M
European session market picture: S&P 500 +0.09%, Nasdaq 100 +0.13%; EUR/USD -0.3%, WTI +0.07%, HSBA leads volume
European session market picture. US index futures: S and P futures is up 0.09 percent, Nasdaq futures is up 0.13 percent, Dow futures is up 0.17 percent and Russell futures is up 0.03 percent. In currencies, the dollar i
EQUITY | Oct 27, 2026, 10:00 AM UTC
M
EU Approves AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer
The European Commission approved Enhertu as an adjuvant monotherapy for HER2-positive early breast cancer.
REGULATION | Oct 27, 2026, 08:31 AM UTC
M
EU Approves Enhertu as Adjuvant Treatment for Early HER2-Positive Breast Cancer
The EU approved Enhertu (trastuzumab deruxtecan) as adjuvant monotherapy for adults with resected HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.
REGULATION | Oct 27, 2026, 07:36 AM UTC
L
Hutchmed, AstraZeneca Say Treatment Reduces Lung Cancer Disease Progression
The companies said their Orpathys plus Tagrisso treatment reduced disease progression in metastatic non-small cell lung cancer.
EQUITY | Oct 26, 2026, 09:32 AM UTC
M
AstraZeneca Says Imfinzi Studies Cut Death Risk by 58% and 42%
AstraZeneca said two phase 3 studies showed Imfinzi cut death risk by 58% and 42% in lung and bladder cancer, respectively.
EQUITY | Oct 26, 2026, 08:27 AM UTC
M
AstraZeneca Drug Extends Survival in Late-Stage Stomach Cancer Study
AstraZeneca’s experimental drug sone-ve helped patients with advanced stomach cancer live longer than analysts had expected, according to late-stage trial data presented Sunday.
EQUITY | Oct 25, 2026, 03:30 PM UTC
M
AstraZeneca Bladder Cancer Treatment Reduced Recurrence Risk 49%
Perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced recurrence risk by 49% and risk of death by 42% in muscle-invasive bladder cancer.
EQUITY | Oct 24, 2026, 02:36 PM UTC
M
AstraZeneca Reports 58% Lower Death Risk With Durvalumab-Tarlatamab in Phase III
AstraZeneca said the combination cut the risk of death by 58% versus IMFINZI alone in first-line maintenance ES-SCLC. Median overall survival was 21.1 months versus 12.7 months; progression or death risk fell 66%.
EARNINGS | Oct 24, 2026, 02:35 PM UTC
M
AstraZeneca VOLGA Phase III Trial Meets EFS and OS Endpoints
AstraZeneca said perioperative Imfinzi plus neoadjuvant enfortumab vedotin met VOLGA Phase III endpoints in MIBC. The trial cut EFS risk by 49% (HR 0.51; p<0.0001) and death risk by 42% (HR 0.58; p=0.0027); median EFS an
EQUITY | Oct 24, 2026, 02:30 PM UTC
M
Amgen Combination Therapy Cuts Death Risk 58% in Lung Cancer Trial
Amgen’s Imdelltra, combined with AstraZeneca’s Imfinzi, reduced the risk of death by 58% versus Imfinzi alone in patients with extensive-stage small cell lung cancer, according to trial data presented at a medical meetin
EQUITY | Oct 24, 2026, 02:30 PM UTC
M
European session market picture: S&P 500 -0.5%, Nasdaq 100 -0.34%; EUR/USD -0.14%, WTI +1.77%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.5 percent, Nasdaq futures is down 0.34 percent, Dow futures is down 0.88 percent and Russell futures is down 0.65 percent. In currencies, the d
EQUITY | Oct 23, 2026, 01:01 PM UTC
M
European session market picture: S&P 500 -0.33%, Nasdaq 100 -0.17%; EUR/USD -0.19%, WTI +1.91%, BP leads volume
European session market picture. US index futures: S and P futures is down 0.33 percent, Nasdaq futures is down 0.17 percent, Dow futures is down 0.75 percent and Russell futures is down 0.61 percent. In currencies, the
EQUITY | Oct 23, 2026, 12:30 PM UTC
M
European session market picture: S&P 500 -0.01%, Nasdaq 100 +0.32%; EUR/USD -0.26%, WTI +0.64%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.01 percent, Nasdaq futures is up 0.32 percent, Dow futures is down 0.38 percent and Russell futures is down 0.28 percent. In currencies, the do
EQUITY | Oct 23, 2026, 09:00 AM UTC
M
European session market picture: S&P 500 +0.06%, Nasdaq 100 +0.4%; EUR/USD -0.19%, WTI +1.01%, LLOY leads volume
European session market picture. US index futures: S and P futures is up 0.06 percent, Nasdaq futures is up 0.4 percent, Dow futures is down 0.29 percent and Russell futures is down 0.25 percent. In currencies, the dolla
EQUITY | Oct 23, 2026, 08:33 AM UTC
M
Treasury Proposes Bans on U.S. Investment in Chinese Biotech, AI
The U.S. Treasury Department proposed restrictions on American investment in Chinese biotech, artificial intelligence and advanced memory chips. The proposal could cut off a source of new drugs for the pharmaceutical ind
REGULATION | Oct 23, 2026, 08:09 AM UTC
M
European session market picture: S&P 500 -0.1%, Nasdaq 100 +0.12%; EUR/USD -0.2%, WTI +1.26%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.1 percent, Nasdaq futures is up 0.12 percent, Dow futures is down 0.42 percent and Russell futures is down 0.3 percent. In currencies, the doll
EQUITY | Oct 23, 2026, 07:39 AM UTC
L
AstraZeneca’s Ultomiris Approved; Zegfrovy Launched
The headline reports approval of AstraZeneca’s Ultomiris and the launch of Zegfrovy.
EQUITY | Oct 23, 2026, 07:01 AM UTC
M
AstraZeneca Launches ZEGFROVY in the US for NSCLC
AstraZeneca said ZEGFROVY is available in the US for adults with EGFR exon 20 insertion-mutated NSCLC after platinum chemotherapy. The FDA granted accelerated approval based on a 46% confirmed response rate in WU-KONG1B.
EQUITY | Oct 22, 2026, 12:11 PM UTC
M
AstraZeneca’s Ultomiris Wins Accelerated US Approval
The FDA granted accelerated approval after a priority review, based on interim Phase III data showing a 43.4% reduction in proteinuria versus placebo at 34 weeks. The regulator said it has not yet been proven whether the
REGULATION | Oct 22, 2026, 10:39 AM UTC
M
AstraZeneca Says Ultomiris Approved in US for IgAN
EQUITY | Oct 22, 2026, 06:27 AM UTC
M
FDA Grants Accelerated Approval to AstraZeneca Kidney Disease Treatment
The FDA approved AstraZeneca’s treatment for adults with immunoglobulin A nephropathy, a rare kidney disease that can lead to renal failure.
REGULATION | Oct 21, 2026, 11:05 PM UTC
M
European session market picture: S&P 500 +0.29%, Nasdaq 100 +0.6%; EUR/USD -0.04%, WTI -0.04%, LLOY leads volume
European session market picture. US index futures: S and P futures is up 0.29 percent, Nasdaq futures is up 0.6 percent, Dow futures is up 0.35 percent and Russell futures is up 0.35 percent. In currencies, the dollar in
EQUITY | Oct 21, 2026, 01:00 PM UTC
M
AstraZeneca Shares Rise 2.7% as Tezspire Data Support Expansion Case
AstraZeneca shares traded at $168.38, up approximately 2.71% on October 20. The Fly reported detailed phase 3 CROSSING results for Tezspire, while the commercial payoff remains unproven.
EQUITY | Oct 20, 2026, 07:43 PM UTC
M
Oracle Shares Rise 2.4% on AstraZeneca AI Collaboration
Oracle shares rose 2.4% at 11: a.m. EST on October 20. The nonbinding arrangement with AstraZeneca explores AI applications in clinical research and care.
EQUITY | Oct 20, 2026, 07:33 PM UTC
M
European session market picture: S&P 500 -0.16%, Nasdaq 100 -0.44%; EUR/USD +0.09%, WTI +0.77%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.16 percent, Nasdaq futures is down 0.44 percent, Dow futures is up 0.02 percent and Russell futures is up 0.04 percent. In currencies, the doll
EQUITY | Oct 20, 2026, 01:00 PM UTC
M
AstraZeneca-Amgen Drug Achieves 69% Remission in Esophageal Disease Trial
Amgen and AstraZeneca said their asthma drug reduced swallowing difficulties and achieved disease remission in 69% of patients with a chronic inflammatory esophageal disorder.
EQUITY | Oct 20, 2026, 01:00 PM UTC
M
European session market picture: S&P 500 -0.24%, Nasdaq 100 -0.66%; EUR/USD +0.09%, WTI +2.06%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.24 percent, Nasdaq futures is down 0.66 percent, Dow futures is down 0.04 percent and Russell futures is down 0.14 percent. In currencies, the
EQUITY | Oct 20, 2026, 12:30 PM UTC
M
European session market picture: S&P 500 +0.1%, Nasdaq 100 -0.18%; EUR/USD +0.17%, WTI +0.64%, LLOY leads volume
European session market picture. US index futures: S and P futures is up 0.1 percent, Nasdaq futures is down 0.18 percent, Dow futures is up 0.32 percent and Russell futures is up 0.13 percent. In currencies, the dollar
EQUITY | Oct 20, 2026, 07:30 AM UTC
L
AstraZeneca Enters $40 Million Drug Discovery Deal With Insitro
The collaboration will identify drug targets and develop therapeutics for MASH and cardiomyopathies. AstraZeneca will make an upfront payment of $40 million.
EQUITY | Oct 15, 2026, 12:51 PM UTC
M
AstraZeneca Strikes AI Drug Discovery Deal Worth Up to $1.5 Billion
AstraZeneca said it will work with Insitro to use AI to explore treatments for cardiometabolic diseases. The deal includes $40 million upfront, with additional payments bringing its value to as much as $1.5 billion.
EQUITY | Oct 15, 2026, 12:20 PM UTC
M
UK Stocks Close Higher as Weaker Sterling Supports Export-Heavy Sectors
The FTSE 100 closed up 0.7% at 10,724.86 points on Wednesday, while the midcap FTSE also ended higher. Healthcare and consumer staples gained as sterling weakened.
EQUITY | Oct 14, 2026, 04:31 PM UTC
M
European session market picture: S&P 500 -0.08%, Nasdaq 100 -0.72%; EUR/USD +0.27%, WTI -1.27%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.08 percent, Nasdaq futures is down 0.72 percent, Dow futures is up 0.71 percent and Russell futures is up 0.28 percent. In currencies, the doll
EQUITY | Oct 13, 2026, 12:02 PM UTC
M
European session market picture: S&P 500 unchanged, Nasdaq 100 -0.46%; EUR/USD +0.22%, WTI -1.81%, LLOY leads volume
European session market picture. US index futures: S and P futures is unchanged at 0 percent, Nasdaq futures is down 0.46 percent, Dow futures is up 0.51 percent and Russell futures is up 0.39 percent. In currencies, the
EQUITY | Oct 13, 2026, 09:03 AM UTC
M
European session market picture: S&P 500 -0.02%, Nasdaq 100 -0.54%; EUR/USD +0.28%, WTI -1.74%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.02 percent, Nasdaq futures is down 0.54 percent, Dow futures is up 0.62 percent and Russell futures is up 0.38 percent. In currencies, the doll
EQUITY | Oct 13, 2026, 08:32 AM UTC
M
European session market picture: S&P 500 -0.04%, Nasdaq 100 -0.62%; EUR/USD +0.27%, WTI -1.64%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.04 percent, Nasdaq futures is down 0.62 percent, Dow futures is up 0.52 percent and Russell futures is up 0.41 percent. In currencies, the doll
EQUITY | Oct 13, 2026, 08:02 AM UTC
M
European session market picture: S&P 500 -0.06%, Nasdaq 100 -0.74%; EUR/USD +0.29%, WTI -1.56%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.06 percent, Nasdaq futures is down 0.74 percent, Dow futures is up 0.58 percent and Russell futures is up 0.38 percent. In currencies, the doll
EQUITY | Oct 13, 2026, 07:32 AM UTC
M
European session market picture: S&P 500 -0.14%, Nasdaq 100 -0.42%; EUR/USD -0.62%, WTI +0.68%, BARC leads volume
European session market picture. US index futures: S and P futures is down 0.14 percent, Nasdaq futures is down 0.42 percent, Dow futures is down 0.35 percent and Russell futures is down 0.51 percent. In currencies, the
EQUITY | Oct 07, 2026, 10:30 AM UTC
M
European session market picture: S&P 500 -0.14%, Nasdaq 100 -0.44%; EUR/USD -0.59%, WTI +0.31%, BARC leads volume
European session market picture. US index futures: S and P futures is down 0.14 percent, Nasdaq futures is down 0.44 percent, Dow futures is down 0.27 percent and Russell futures is down 0.46 percent. In currencies, the
EQUITY | Oct 07, 2026, 10:00 AM UTC
M
European session market picture: S&P 500 +0.02%, Nasdaq 100 -0.2%; EUR/USD -0.57%, WTI +0.02%, BARC leads volume
European session market picture. US index futures: S and P futures is up 0.02 percent, Nasdaq futures is down 0.2 percent, Dow futures is down 0.04 percent and Russell futures is down 0.11 percent. In currencies, the dol
EQUITY | Oct 07, 2026, 09:00 AM UTC
M
European session market picture: S&P 500 +0.02%, Nasdaq 100 -0.13%; EUR/USD -0.61%, WTI -0.02%, LLOY leads volume
European session market picture. US index futures: S and P futures is up 0.02 percent, Nasdaq futures is down 0.13 percent, Dow futures is down 0.07 percent and Russell futures is down 0.12 percent. In currencies, the do
EQUITY | Oct 07, 2026, 08:32 AM UTC
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
AstraZeneca Hedges Threat to Oncology Portfolio — Market Talk
AstraZeneca is hedging against a key threat to its antibody drug conjugate portfolio through its collaboration with Summit Therapeutics, Citi analysts say in a research note. The agreement has limited immediate impact, b
NEWS | Sep 30, 2026, 08:45 AM UTC
L
Key facts: Mid-Nov U.S. decision on ivonescimab; AstraZeneca (AZN) up
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
NEWS | Sep 30, 2026, 07:01 AM UTC
L
AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology
AstraZeneca NYSE:AZN, the oncology and biopharmaceutical company, agreed to invest $2 billion in Summit Therapeutics to test new cancer drug combinations. Its shares were down about 0.7% at $164.95 at 9.55am EST time on
EQUITY | Sep 29, 2026, 05:18 PM UTC
H
FTSE 100 hits two-week low as energy stocks slide
London's FTSE 100 slipped to a two-week low on Tuesday, dragged down by heavyweight energy stocks as oil prices retreated, while British American Tobacco fell after issuing downbeat guidance.The blue-chip FTSE 100 index
COMMODITIES | Sep 29, 2026, 04:25 PM UTC